US Markets

Novartis CEO says COVID-19 makes valuing takeover targets tougher

Credit: REUTERS/ARND WIEGMANN

Swiss drugmaker Novartis AG has financial firepower for acquisitions even with net debt of $26 billion, though the COVID-19 pandemic has made it more difficult to value takeover candidates, Chief Executive Vas Narasimhan said in an interview.

ZURICH, Aug 24 (Reuters) - Swiss drugmaker Novartis AG NOVN.S has financial firepower for acquisitions even with net debt of $26 billion, though the COVID-19 pandemic has made it more difficult to value takeover candidates, Chief Executive Vas Narasimhan said in an interview.

"We generate a high free cash flow that allows us to not only finance our dividend but to direct capital to other purposes," Narasimhan told the Swiss newspaper Neue Zuercher Zeitung.

Still, "acquisitions have slowed recently from a structural perspective" during the pandemic, he said.

Narasimhan, a U.S. citizen who took over two years ago as CEO, acknowledged disappointment that Novartis' existing medicines had not proven more useful against COVID-19. For instance, the company, like others, abandoned a trial of its older malaria medicine hydroxychloroquine after it failed to help patients in scientific studies.

Moreover, he said Novartis had hoped to be faster in developing new drugs against COVID-19 and could have potentially profited from more cooperation with smaller biotech companies. "We concentrated more on our own in-house activities - and learned a lesson from it," he said.

Many of the medicines that Novartis is supplying for patients stricken with COVID-19 come from its Sandoz generics unit. For now, Narasimhan said Novartis is not interested in selling Sandoz, but rather continuing work to boost its sales and profit margins squeezed by U.S. price pressure.

"We believe at this time that we can do this best with Sandoz within the Novartis group," he told the newspaper.

Novartis' share price has fallen 15% this year, compared to peer Roche Holding AG's ROG.S 2% rise.

Beyond recent legal settlements in corruption cases that topped $1 billion, Narasimhan believes safety problems that emerged with new eye medicine Beovu have cost Novartis shares 10% of their value.

"Challenge No. 1 was Beovu's launch," he said.

(Reporting by John Miller; Editing by Christopher Cushing)

((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NOVN ROG

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More